Back to top
more

LeMaitre Vascular (LMAT)

(Delayed Data from NSDQ)

$101.71 USD

101.71
237,196

+3.08 (3.12%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $101.68 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks News

Earnings Preview: LeMaitre Vascular (LMAT) Q2 Earnings Expected to Decline

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ritujay Ghosh headshot

Trump Pushes for US-Made Medical Products: 4 Winners

An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.

LeMaitre Vascular (LMAT) Meets Q1 Earnings Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -2.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: LeMaitre Vascular (LMAT) Q1 Earnings Expected to Decline

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Walgreens U.S. Retail Pharmacy Rises Amid Reimbursement Woes

Intensifying competition in the U.S. retail drugstore market prompts Walgreens Boots (WBA) to diversify its product offerings.

LabCorp (LH) Rides on Solid Diagnostics Despite PAMA Issues

LabCorp's (LH) Covance Drug Development delivers organic growth despite foreign currency headwind.

Here's Why You Should Add Zimmer (ZBH) to Your Portfolio

Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.

Hologic Expands Panther Portfolio With New Product Offerings

Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.

LeMaitre Vascular (LMAT) Q4 Earnings Match Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -1.05%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EYE vs. LMAT: Which Stock Is the Better Value Option?

EYE vs. LMAT: Which Stock Is the Better Value Option?

Here's Why You Should Add ResMed (RMD) to Your Portfolio

Investors continue to be optimistic about ResMed's (RMD) performance.

LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Beat Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 19.05% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Reports Next Week: What to Know Ahead of the Release

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EYE vs. LMAT: Which Stock Should Value Investors Buy Now?

EYE vs. LMAT: Which Stock Is the Better Value Option?

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

Investors continue to be optimistic about Chemed's (CHE) performance.

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.

Here's Why You Should Add Abbott (ABT) to Your Portfolio

Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.

Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety

Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.

NuVasive's New TLIF Implant Broadens Spine Surgery Option

NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.

Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod

Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.

Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up

Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.

National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down

National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.

Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View

Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.

Moving Average Crossover Alert: LeMaitre Vascular

LeMaitre Vascular, Inc. (LMAT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.